Asahi Kasei to Realign Material Supply by FY2030

Key highlights
  • Streamline operations at Mizushima Works and realign derivative-product supply chains by fiscal 2030; company says there is no immediate impact on supply.
  • Exit low-margin derivative businesses (¥116.2bn revenue in FY2025 vs. ¥1,306.2bn for the Material segment) to improve margins and reduce cash outflows.
  • Actions follow cessation of ethylene production at AMEC and include collaboration with Mitsui Chemicals and Mitsubishi Chemical on ethylene decarbonization.

Restructuring plan

Asahi Kasei will streamline operations at its Mizushima Works and realign derivative-product supply chains by fiscal 2030; the company says there will be no immediate impact on supply of derivative products.

Financial scope

The businesses covered recorded ¥116.2 billion revenue in fiscal 2025 against ¥1,306.2 billion for the Material segment overall; the move targets exit from low‑margin derivative businesses to improve margins and reduce cash outflows.

Strategic context

The measures follow the previously announced cessation of ethylene production at Asahi Kasei Mitsubishi Chemical Ethylene Corp. (AMEC) and form part of the three‑year medium‑term management plan “Trailblaze Together,” which aims to enhance capital efficiency and reallocate resources to pharmaceuticals, critical care, overseas homes and electronics.

Recent related actions

Recent steps cited include a basic agreement with Mitsui Chemicals and Mitsubishi Chemical to promote decarbonization of ethylene production in western Japan and the acquisition of Aicuris to bolster the company’s specialty pharmaceutical capabilities in severe infectious diseases.

Source: Asahi Kasei

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

12 May 2026
Asahi Kasei, Mitsui Chemicals and Mitsubishi Chemical agree 45/45/10 equity split for western Japan ethylene JV

Plan to integrate western Japan ethylene assets: close Mizushima plant by 2030 and consolidate operations at a single site to decarbonize, optimize capacity and strengthen competitiveness.

27 January 2026
Asahi Kasei, Mitsui, and Mitsubishi Collaborate on Decarbonizing Ethylene Production in Japan

The companies plan to consolidate ethylene production, use bioethanol, and dismantle outdated facilities to enhance decarbonization and optimize operations by 2034.

27 January 2026
Asahi Kasei, Mitsui, and Mitsubishi to Merge Ethylene Production

The companies will consolidate ethylene production in western Japan, aiming for decarbonization by using biomass feedstock and Revolefin™ technology, targeting fiscal 2030 and 2034 milestones.

1 September 2025
Asahi Kasei, Mitsui, and Mitsubishi Form LLP for Ethylene Production in Japan

The LLP aims for carbon neutrality and optimized ethylene production by 2030, focusing on biomass feedstocks, low-carbon fuels, and potential capacity reductions.

30 September 2026
Asahi Kasei consolidates pharmaceutical units under Asahi Kasei Therapeutics

Brings acquired specialty-pharma units into a single global management to pursue niche immunology, nephrology, transplant and infectious disease markets; targets ¥300bn by FY2030.